Original scientific paper
Candida Distribution in Onychomycosis and in vitro Susceptibility to Antifungal Agents
Algimantas Paškevičius
; Laboratory of Biodeterioration Research, Nature Research Centre, Vilnius, Lithuania
Jurgita Švedienė
Silvija Kiverytė
; Laboratory of Microbiology, Centre of Laboratory Medicine, Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania
Danguolė Bridžiuvienė
; Laboratory of Biodeterioration Research, Nature Research Centre, Vilnius, Lithuania
Gintautas Vaitonis
; Laboratory of Biodeterioration Research, Nature Research Centre, Vilnius, Lithuania
Valerija Jablonskienė
; Department of Physiology, Biochemistry, Microbiology and Laboratory Medicine, Vilnius University, Vilnius, Lithuania
Abstract
The aim of this study was to determine distribution
of the Candida (C.) species in onychomycosis and analyses
in vitro susceptibility to fluconazole and itraconazole.
In recent years, cases of onychomycosis in Lithuania caused
by Candida have increased significantly. In the period between
2009 and 2016, a total of 8149 clinical cases (outpatients
and inpatients) were investigated at the Vilnius University
Hospital Santaros Clinics (VUH SC). Candida yeasts
were identified using VITEK 2 (BioMerieux, France) and IVD
Maldi biotyper 2.3 (Bruker Daltonik GmbH, Germany), automated
systems for identification of yeasts. The antifungal
susceptibility to the Candida species were determined by
disc diffusion. Candida spp. were the most frequently isolated
pathogens in onychomycosis during the investigation
period. The main species in onychomycosis were C. albicans
(38.6%), followed by C. krusei (33.7%), C. tropicalis (11.1%), C.
parapsilosis (7.9%), and other Candida (8.7%). The different
antifungal susceptibility patterns among Candida species
confirm the need to perform antifungal susceptibility in vitro
testing of yeasts from patients with onychomycosis
Keywords
onychomycosis, prevalence, Candida, antifungal
Hrčak ID:
255071
URI
Publication date:
30.12.2020.
Visits: 1.360 *